In our study, the KRAS mutation rate was extremely low in both the entire patient group (53 of 1033, 5.13%) and the adenocarcinoma patient group (45 of 759, 5.93%), which is consistent with a previous conclusion that Asians exhibit a lower frequency of KRAS mutations. The gene discussed is KRAS; the disease is adenocarcinoma.